Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action

References

• Yamada A, Wang J, Komaki Y, et al. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019;50(4):373–385.
   PubMed Web of Science ®Google Scholar
• Petitpain N, D’Amico F, Yelehe-Okouma M, et al. IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in vigibase. Clin Pharmacol Ther. 2021;110:159–168.
   PubMed Web of Science ®Google Scholar
• Ehrlich D, Jamaluddin N, Pisegna J, et al. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med. 2018;2018:9679287. Published 2018 Feb 15.
   PubMed Web of Science ®Google Scholar
• Rodríguez Moncada R, Vázquez Morón JM, Pallarés Manrique H. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease? Rev Esp Enferm Dig. 2019;111(9):720–721.
   PubMed Web of Science ®Google Scholar
• Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018;12(9):1131–1133.
   PubMed Web of Science ®Google Scholar
• Wang J, Bhatia A, Krugliak Cleveland N, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J. 2018;5:e56. Published 2018 Aug 1.
   PubMed Web of Science ®Google Scholar
• Smith MK, Pai J, Panaccione R, et al. Crohn’s-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162. Published 2019 Sep 5.
   PubMed Web of Science ®Google Scholar
• Ju J, Dai Y, Yang J, et al. Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report. BMC Gastroenterol. 2020;20(1):340. Published 2020 Oct 15.
   PubMed Web of Science ®Google Scholar
• Onac IA, Clarke BD, Tacu C, et al. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients [published online ahead of print, 2021 Mar 2]. Rheumatology (Oxford). 2021;keab193. DOI:https://doi.org/10.1093/rheumatology/keab193.
   Google Scholar
• Lee JS, Tato CM, Joyce-Shaikh B, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015 Oct 20;43(4):727–738. Epub 2015 Sep 29. Erratum in: Immunity. 2015 Nov 17;43(5):1022.Gulan, Fatih [corrected to Gulen, Muhammet F]. PMID: 26431948; PMCID: PMC6044435.
   PubMed Web of Science ®Google Scholar
• Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 pathway in Crohn’s disease. Front Immunol. 2021;12:622934. Published 2021 Mar 30.
   PubMed Web of Science ®Google Scholar
• Chandra A, Ray A, Senapati S, et al. Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol. 2015;64(2):313–323.
   PubMed Web of Science ®Google Scholar
• Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009;41(12):1335–1340.
   PubMed Web of Science ®Google Scholar
• Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013;2013:983902.
   PubMed Web of Science ®Google Scholar
• Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis (Auckl). 2016;6:73–92. Published 2016 Jul 20.
   PubMedGoogle Scholar
• Alinaghi F, Tekin HG, Burisch J, et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis. J Crohns Colitis. 2020;14(3):351–360.
   PubMed Web of Science ®Google Scholar
• Kumar AM, Chiou AS, Shih YH, et al. An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183(5):942–943.
   PubMed Web of Science ®Google Scholar
• Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524–1526.
   PubMed Web of Science ®Google Scholar
• Lo B, Vind I, Vester-Andersen MK, et al. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a Danish population-based inception cohort. J Crohns Colitis. 2020;14(1):53–63.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Griffiths AM. Clinical value of fecal calprotectin. Crit Rev Clin Lab Sci. 2019;56(5):307–320.
   PubMed Web of Science ®Google Scholar
• Premjeyanth V, Shipman AR, Shipman KE. Faecal calprotectin in dermatology practice. Clin Exp Dermatol. 2020;45(7):831–835.
   PubMed Web of Science ®Google Scholar
• Adarsh MB, Dogra S, Vaiphei K, et al. Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019;181(2):401–402.
   PubMed Web of Science ®Google Scholar
• Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Bonovas S, Danese S, et al. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(7):689–698.
   PubMed Web of Science ®Google Scholar
• Fries W, Belvedere A, Cappello M, et al. Inflammatory bowel disease onset during secukinumab treatment: real concern or just an expression of dysregulated immune response? Clin Drug Investig. 2019;39(8):799–803.
   PubMed Web of Science ®Google Scholar
• Fauny M, D’Amico F, Bonovas S, et al. Calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. J Crohns Colitis. 2020;14(5):688–693.
   PubMed Web of Science ®Google Scholar
• Gettler K, Levantovsky R, Moscati A, et al. Common and rare variant prediction and penetrance of IBD in a large, multi-ethnic, health system-based biobank cohort. Gastroenterology. 2020;S0016-5085(20)35575-X. DOI:https://doi.org/10.1053/j.gastro.2020.12.034.
   Google Scholar
• Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979–986.
   PubMed Web of Science ®Google Scholar
• Frenkel S, Bernstein CN, Sargent M, et al. Genome-wide analysis identifies rare copy number variations associated with inflammatory bowel disease. PLoS One. 2019;14(6):e0217846. Published 2019 Jun 11.
   PubMed Web of Science ®Google Scholar
• Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet. 2007;39(7):830–832.
   PubMed Web of Science ®Google Scholar
• Glas J, Wagner J, Seiderer J, et al. PTPN2 gene variants are associated with susceptibility to both Crohn’s disease and ulcerative colitis supporting a common genetic disease background. PLoS One. 2012;7(3):e33682.
   PubMed Web of Science ®Google Scholar
• de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256–261.
   PubMed Web of Science ®Google Scholar
• Chen GB, Lee SH, Montgomery GW, et al. Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. BMC Med Genet. 2017;18(1):94.
   PubMedGoogle Scholar
• Morelli M, Galluzzo M, Madonna S, et al. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opin Biol Ther. 2021;21(2):259–270.
   PubMed Web of Science ®Google Scholar